Filtered By:
Specialty: Drugs & Pharmacology
Drug: Melatonin
This page shows you your search results in order of date.
Order by Relevance | Date
Total 480 results found since Jan 2013.
Melatonin as a therapeutic agent for alleviating endothelial dysfunction in cardiovascular diseases: Emphasis on oxidative stress
Biomed Pharmacother. 2023 Sep 16;167:115475. doi: 10.1016/j.biopha.2023.115475. Online ahead of print.ABSTRACTThe vascular endothelium is vital in maintaining cardiovascular health by regulating vascular permeability and tone, preventing thrombosis, and controlling vascular inflammation. However, when oxidative stress triggers endothelial dysfunction, it can lead to chronic cardiovascular diseases (CVDs). This happens due to oxidative stress-induced mitochondrial dysfunction, inflammatory responses, and reduced levels of nitric oxide. These factors cause damage to endothelial cells, leading to the acceleration of CVD progr...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 18, 2023 Category: Drugs & Pharmacology Authors: Xiaolu Zhang Yujia Zheng Ziyu Wang Jiali Gan Bin Yu Bin Lu Xijuan Jiang Source Type: research
Intratumoral injection of melatonin enhances tumor regression in cell line-derived and patient-derived xenografts of head and neck cancer by increasing mitochondrial oxidative stress
Biomed Pharmacother. 2023 Sep 15;167:115518. doi: 10.1016/j.biopha.2023.115518. Online ahead of print.ABSTRACTHead and neck squamous cell carcinoma present a high mortality rate. Melatonin has been shown to have oncostatic effects in different types of cancers. However, inconsistent results have been reported for in vivo applications. Consequently, an alternative administration route is needed to improve bioavailability and establish the optimal dosage of melatonin for cancer treatment. On the other hand, the use of patient-derived tumor models has transformed the field of drug research because they reflect the heterogenei...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 17, 2023 Category: Drugs & Pharmacology Authors: Laura Martinez-Ruiz Javier Florido C ésar Rodriguez-Santana Alba L ópez-Rodríguez Ana Guerra-Librero Beatriz I Fern ández-Gil Patricia Garc ía-Tárraga Jos é Manuel Garcia-Verdugo Felix Oppel Holger Sudhoff David S ánchez-Porras Amadeo Ten-Steve Jo Source Type: research
Melatonin ameliorates atherosclerosis by suppressing S100a9-mediated vascular inflammation
Eur J Pharmacol. 2023 Aug 23:175965. doi: 10.1016/j.ejphar.2023.175965. Online ahead of print.ABSTRACTAtherosclerosis (AS)-associated cardiovascular diseases are predominant causes of morbidity and mortality worldwide. Melatonin, a circadian hormone with anti-inflammatory activity, may be a novel therapeutic intervention for AS. However, the exact mechanism is unclear. This research intended to investigate the mechanism of melatonin in treating AS. Melatonin (20 mg/kg/d) was intraperitoneally administered in a high-fat diet (HFD)-induced AS model using apolipoprotein E-deficient (ApoE-/-) mice for 12 weeks. Immunohistochem...
Source: European Journal of Pharmacology - August 25, 2023 Category: Drugs & Pharmacology Authors: Liyuan Chen Xue Wang Chang Liu Ping Deng Lina Pan Lingling Yang Juan Cheng Xutao Zhang Russel J Reiter Zhengping Yu Huifeng Pi Zhou Zhou Houyuan Hu Source Type: research
Melatonin as a potential treatment for septic cardiomyopathy
Biomed Pharmacother. 2023 Aug 22;166:115305. doi: 10.1016/j.biopha.2023.115305. Online ahead of print.ABSTRACTSeptic cardiomyopathy (SCM) is a common complication of sepsis contributing to high mortality rates. Its pathophysiology involves complex factors, including inflammatory cytokines, mitochondrial dysfunction, oxidative stress, and immune dysregulation. Despite extensive research, no effective pharmacological agent has been established for sepsis-induced cardiomyopathy. Melatonin, a hormone with diverse functions in the body, has emerged as a potential agent for SCM through its anti-oxidant, anti-inflammatory, anti-a...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - August 24, 2023 Category: Drugs & Pharmacology Authors: Amira Mohamed Taha Abdelrahman Mohamed Mahmoud Mohamed M Ghonaim Ateeba Kamran Jehad Feras AlSamhori Majd M AlBarakat Abhigan Babu Shrestha Vikash Jaiswal Russel J Reiter Source Type: research
Downregulation of PDCD4 through STAT3/ATF6/autophagy mediates MIF-induced PASMCs proliferation/migration and vascular remodeling
In conclusions, we demonstrate that MIF activates the STAT3/ATF6/autophagy cascade and then degrades PDCD4 leading to PASMCs proliferation/migration and pulmonary vascular remodeling, suggesting that intervention this axis might have potential value in management of PH.PMID:37549728 | DOI:10.1016/j.ejphar.2023.175968
Source: European Journal of Pharmacology - August 7, 2023 Category: Drugs & Pharmacology Authors: Limin Chai Qingting Wang Yan Wang Danyang Li Qianqian Zhang Yuqian Chen Jin Liu Huan Chen Yuanjie Qiu Nirui Shen Jian Wang Xinming Xie Manxiang Li Source Type: research
Potential therapeutic role of melatonin in hepatobiliary diseases: current evidence and clinical observations
J Physiol Pharmacol. 2023 Apr;74(2). doi: 10.26402/jpp.2023.2.01. Epub 2023 Jul 10.ABSTRACTMelatonin (MEL) is produced and secreted by the pineal gland as well as the small intestine, liver, retina, lymphocytes, and melanocytes in the skin in both experimental animals as well as in humans. While pineal and retinas MEL is closely related to the light/dark cycle, the production of MEL by other so called extrapineal tissues is independent of such circadian rhythm. Among the primary mechanisms of action of MEL in humans, the most important are interaction of MEL with specific receptors (M1, M2, M3) and the MEL 'scavenging' act...
Source: J Physiol Pharmacol - July 15, 2023 Category: Drugs & Pharmacology Authors: M Gonciarz I Lombard L Konecki P Gietka R Pajdo T Brzozowski Source Type: research
